Indication
Synvisc-One® (hylan G-F 20) and SYNVISC® (hylan G-F 20) are indicated for the treatment
of pain in osteoarthritis (OA) of the knee in patients who have failed to respond
adequately to conservative non-pharmacologic therapy and simple analgesics, e.g.,
acetaminophen.
Important Safety Information
Before trying Synvisc-One or SYNVISC, tell your doctor if you are allergic to products
from birds—such as feathers, eggs or poultry—or if your leg is swollen or infected.
Synvisc-One and SYNVISC are only for injection into the knee, performed by a doctor
or other qualified health care professional. Synvisc-One and SYNVISC have not been
tested to show pain relief in joints other than the knee. Talk to your doctor before
resuming strenuous weight-bearing activities after treatment. Synvisc-One
and SYNVISC have not been tested in children, pregnant women or women who are nursing.
You should tell your doctor if you think you are pregnant or if you are nursing
a child. The side effects most commonly seen when Synvisc-One or SYNVISC is
injected into the knee were pain, swelling and/or fluid buildup in or around the
knee. Cases where the swelling is extensive or painful should be discussed with
your doctor. Allergic reactions such as rash and hives have been reported
rarely.
View the Complete Prescribing Information for Synvisc-One (PDF)
View the Complete Prescribing Information for SYNVISC
(PDF)
Hyalgan is a registered trademark of Fidia S.P.A.
Supartz is a registered trademark of Seikugaku.
Orthovisc is a registered trademark of Anika Therapeutics Inc.
Euflexxa is a trademark of Ferring Pharmaceuticals, Inc.
Celebrex is a registered trademark of Pfizer Inc.